Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma
A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects in Europe With Unresected Stage IIIB to IVM1c Melanoma
Sponsor: Amgen
This observational or N/A phase trial investigates Unresected Stage IIIB to IVM1c Melanoma and is currently ongoing. Amgen leads this study, which shows 10 recorded versions since 2026 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
No Longer Available
-
Sep 2024 — Sep 2025 [monthly]
No Longer Available
-
Jul 2024 — Sep 2024 [monthly]
No Longer Available
-
Jan 2021 — Jul 2024 [monthly]
No Longer Available
-
Nov 2019 — Jan 2021 [monthly]
No Longer Available
▶ Show 5 earlier versions
-
Jun 2018 — Nov 2019 [monthly]
No Longer Available
-
Apr 2018 — Jun 2018 [monthly]
No Longer Available
Phase: NA → None
-
Jul 2017 — Apr 2018 [monthly]
No Longer Available NA
Status: Available → No Longer Available
-
Mar 2017 — Jul 2017 [monthly]
Available NA
Phase: PHASE3 → NA
-
Jan 2017 — Mar 2017 [monthly]
Available PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Amgen
For direct contact, visit the study record on ClinicalTrials.gov .